Clinical trials: Depressive; Behavioral Disorder
Depression, Major Depressive Disorder
Novel Neural Circuit Biomarkers of Major Depression Response to CCBT
The purpose of the study is to learn more about computer-assisted cognitive behavioral therapy or "CCBT" and to examine connections in the brains of patients with depression.
- Conditions
- Depression, Major Depressive Disorder, Depressive Disorder, Depression, Unipolar
- Trial name
- NCT03096886
- Testing
- Computer-Augmented Cognitive Behavioral Therapy
- Where
- United States
- Volunteers
- 132 people, healthy volunteers welcome
- Sponsor
- University of Pennsylvania
Depression
Paroxetine/Bupropion in Suicide Attempters/Ideators With Major Depression
The primary study comparing effectiveness for suicidal ideation and/or behavior of two antidepressant medications in depressed patients who have attempted suicide or are currently experiencing suicidal thoughts has been…
- Trial name
- NCT00429169
- Testing
- Paroxetine, Bupropion
- Where
- United States
- Volunteers
- 101 people
- Sponsor
- New York State Psychiatric Institute
Major Depressive Disorder
A Study of Vortioxetine (Lu AA21004) in Comparison to Agomelatine in Adults Suffering From Major Depression With Inadequate Response to Previous Medication
The objective of the present study is to evaluate whether vortioxetine (10 or 20 mg/day) is at least as effective as agomelatine (25 to 50 mg/day) in patients with depressive symptoms that showed inadequate response to Serotonin…
- Trial name
- REVIVE (NCT01488071)
- Testing
- Vortioxetine (Lu AA21004), Agomelatine
- Volunteers
- 495 people
- Sponsor
- H. Lundbeck A/S
Depression
Safety and Effectiveness of S-adenosyl-l-methionine (SAMe) for the Treatment of Major Depression
The purpose of this study is to determine the safety and effectiveness of s-adenosyl-l-methionine (SAMe) in treating major depression.
- Trial name
- NCT00101452
- Testing
- S-adenosyl-l-methionine, Escitalopram
- Where
- 2 sites in United States
- Volunteers
- 199 people
- Sponsor
- Maurizio Fava, MD
Major Depressive Disorder
Efficacy and Safety of Cranial Electrical Stimulation (CES) for Major Depressive Disorder (MDD)
The purpose of this study is to see if using Cranial Electrical Stimulation (CES) helps improve symptoms of major depressive disorder (MDD).
- Trial name
- NCT01325532
- Testing
- Active CES
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Massachusetts General Hospital
Depressive Disorder, Anxiety
An Efficacy, Safety and Tolerability Study of JNJ-42165279 in Participants With Major Depressive Disorder With Anxious Distress
The purpose of this study is to evaluate the efficacy and safety and tolerability of JNJ-42165279 in participants with major depressive disorder (MDD) with anxiety symptoms who have had inadequate response to treatment with a…
- Trial name
- NCT02498392
- Testing
- JNJ-42165279
- Where
- 32 sites in United States, Moldova and 4 more
- Volunteers
- 161 people
- Sponsor
- Janssen Research & Development, LLC
Depressive Disorder, Depression
Study of the Safety and Efficacy of Two Fixed Doses of OPC-34712 as Adjunctive Therapy in the Treatment of Adults With Major Depressive Disorder (the Polaris Trial)
To compare the effect of OPC-34712 (brexpiprazole) to the effect of placebo (an inactive substance) as add on treatment to an assigned FDA approved antidepressant treatment (ADT) in patients with Major Depressive Disorder who…
- Conditions
- Depressive Disorder, Depression, Depressive Disorder, Major, Mood Disorders
- Trial name
- Polaris (NCT01360632)
- Testing
- OPC-34712 + ADT
- Where
- 71 sites in United States, Canada and 5 more
- Volunteers
- 1,539 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Major Depressive Disorder, Bipolar Disorder
The Role of Dopamine Metabolism in the Antidepressant Effects of Sleep Deprivation and Sertraline in Depressed Patients
This study evaluates the efficacy of sleep deprivation treatment in accelerating antidepressant responses when administered during the first week of medications and augmenting a sustained response with chronobiological…
- Trial name
- NCT00581009
- Testing
- chronobiological augmentation, sertraline, lithium, one night of sleep deprivation and two FDG PET scans
- Where
- 2 sites in United States
- Volunteers
- 49 people, healthy volunteers welcome
- Sponsor
- University of California, Irvine
Depression
Brain Energy Metabolism in Individuals With Major Depressive Disorder Receiving Escitalopram
This study will evaluate changes in brain energy metabolism due to treatment with escitalopram in people with major depressive disorder.
- Trial name
- NCT00183677
- Testing
- Escitalopram
- Where
- United States
- Volunteers
- 97 people, healthy volunteers welcome
- Sponsor
- Massachusetts General Hospital
Alcohol Use Disorder, Depressive Disorder
Intermittent Theta Burst for the Treatment of Alcohol Use Disorders in Veterans
The purpose of this study is to evaluate the efficacy of intermittent theta burst repetitive transcranial magnetic stimulation (iTBS) as a treatment for Veterans with an alcohol use disorder (AUD) to decrease the exceedingly high…
- Conditions
- Alcohol Use Disorder, Depressive Disorder, Cigarette Smoking
- Trial name
- NCT03291431
- Testing
- Intermittent theta burst transcranial magnetic stimulation
- Where
- 2 sites in United States
- Volunteers
- 17 people
- Sponsor
- Stanford University
Bipolar Disorder
A Study to Evaluate the Effectiveness and Safety of Extended-Release (ER) Paliperidone Compared With Placebo in Delaying the Recurrence of Symptoms in Bipolar I Disorder
The purpose of this study is to evaluate the effectiveness and safety of oral extended-release (ER) paliperidone compared with placebo in the prevention of the recurrence of mood symptoms in patients with Bipolar I Disorder who…
- Trial name
- NCT00490971
- Testing
- Olanzapine, Paliperidone ER
- Where
- 78 sites in United States, Bulgaria and 14 more
- Volunteers
- 768 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Treatment Outcome
Vortioxetine (Lu AA21004) 10 and 20 mg for Treatment of Major Depressive Disorder With Sexual Dysfunction
The purpose of this study is to evaluate the effects of Vortioxetine (Lu AA21004), once daily (QD), compared with escitalopram on sexual functioning.
- Trial name
- NCT01364649
- Testing
- Vortioxetine, Escitalopram
- Where
- 62 sites in United States, Canada
- Volunteers
- 447 people
- Sponsor
- Takeda
Depressive Episodes, Bipolar I Depression
A Clinical Study of an Investigational Drug for the Treatment of Major Depressive Episode Associated With Bipolar I Disorder.
A clinical trial to study the efficacy and safety of an investigational drug in people with major depressive episodes associated with with Bipolar I disorder (bipolar I depression) Participants in the study will either receive…
- Trial name
- NCT05169710
- Testing
- SEP-4199 CR 200 mg, SEP-4199 CR 400 mg
- Where
- 89 sites in United States, Bulgaria and 4 more
- Volunteers
- 83 people
- Sponsor
- Sumitomo Pharma America, Inc.
Major Depressive Disorder
Study Evaluating Safety and Efficacy of Ropanicant in MDD Patients
This is an open-label, parallel-group study to evaluate the safety and efficacy of Ropanicant in participants with moderate to severe Major Depressive Disorder (MDD).
- Trial name
- NCT06126497
- Testing
- Ropanicant
- Where
- 10 sites in United States
- Volunteers
- 41 people
- Sponsor
- Suven Life Sciences Limited
Post Traumatic Stress Disorder, Major Depressive Disorder
Accelerated TMS to a Novel Brain Target in MDD and PTSD
This is a Clinical Trial designed to evaluate novel transcranial magnetic stimulation (TMS) methods for treating depression/PTSD. TMS is an FDA-approved procedure for treatment-resistant depression.
- Trial name
- NCT03114891
- Testing
- Transcranial Magnetic Stimulation (TMS), Task, fMRI-guided TMS target
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- University of Pennsylvania
Depression
Evaluating the Effectiveness of Escitalopram to Prevent Depression in Head and Neck Cancer Patients Receiving Treatment
This study will evaluate the effectiveness of escitalopram to prevent depression in head and neck cancer patients receiving treatment.
- Trial name
- PROTECT (NCT00536172)
- Testing
- Escitalopram
- Where
- United States
- Volunteers
- 160 people
- Sponsor
- University of Nebraska
Depressive Disorder, Major
A Study to Evaluate the Efficacy of Sage-217 in the Treatment of Adult Participants With Major Depressive Disorder (MDD)
The purpose of this study to evaluate the efficacy of SAGE-217 in the treatment of participants with MDD.
- Trial name
- NCT04442490
- Testing
- SAGE-217
- Where
- 39 sites in United States
- Volunteers
- 543 people
- Sponsor
- Biogen
Depressive Disorder, Violence
Text-Message-Based Depression Prevention for High-Risk Youth in the ED
The purpose of this randomized controlled study is to evaluate acceptability and feasibility, and to gather preliminary data about efficacy, of "iDOVE," a brief emergency department introductory session + longitudinal automated…
- Trial name
- iDOVE (NCT02332239)
- Testing
- iDOVE Intervention (ED+text), Control (EUC)
- Where
- United States
- Volunteers
- 116 people
- Sponsor
- Rhode Island Hospital
Major Depressive Disorder, Anxiety Disorders
IntelliCare: Artificial Intelligence in a Mobile Intervention for Depression and Anxiety (AIM)
This study will evaluate a Smartphone intervention for depression and anxiety that uses machine learning to tailor treatment for patients.
- Trial name
- NCT02176226
- Testing
- IntelliCare
- Where
- United States
- Volunteers
- 105 people
- Sponsor
- Northwestern University
Major Depressive Disorder
A 6-Month Extension Study To The B2061032 Study To Evaluate The Safety, Tolerability, And Efficacy Of DVS SR In The Treatment Of Child And Adolescent Outpatients With MDD
This is a 6-month, open-label, flexible-dose study evaluating Desvenlafaxine Succinate Sustained-Release (DVS SR) in the Treatment of Child and Adolescent Outpatients with Major Depressive Disorder (MDD).
- Trial name
- NCT01371708
- Testing
- DVS SR
- Where
- 36 sites in United States, Chile
- Volunteers
- 283 people
- Sponsor
- Pfizer